Chinese fashion company Shein to make US debut in the biggest IPO in years
\nErectile dysfunction biotech LTR Pharma is expected to list next week
\nWe look at other upcoming IPO listings on the ASX<\/p>\n
\u00a0<\/p>\n
Shares of newly listed German sandal maker Birkenstock\u00a0(NYSE:BIRK)<\/strong> have risen by almost 20% since its debut in October.<\/p>\n The stock has benefited from strong spending by US shoppers during the Thanksgiving<\/em> holiday, as well as Black Friday<\/em> and Cyber Monday<\/em>.<\/p>\n But despite its grand entrance as a public company, Birkenstock shares are actually heavily shorted in the market. According to data from analytics firm Ortex<\/strong>, 5.71 million shares of Birkenstock (worth roughly US$260 million) are shorted.<\/p>\n The company is backed by French billionaire Bernard Arnault<\/em> and his luxury goods empire Louis Vuitton Moet Hennessy (LVMH).<\/em><\/p>\n Meanwhile, another fashion juggernaut, Shein<\/strong>, is expected to go public in the US \u00a0at some point in 2024.<\/p>\n Founded in China in 2012 by little known entrepreneur Chris Xu, Shein is an e-commerce fashion house headquartered in Singapore with revenue of US$23 billion in 2022.<\/p>\n The company is known for its $10 tops and $5 biker shorts, has a massive online advertising presence, and ships the majority of its products directly from China to more than a hundred countries.<\/p>\n JPMorgan Chase<\/em>, Morgan Stanley<\/em> and Goldman Sachs<\/em> have reportedly been hired as underwriters for the IPO, and Bloomberg reports that a valuation of US$80-90bn<\/strong> could be on the cards.<\/p>\n This would make Shein the largest initial public offering in years.<\/p>\n \u00a0<\/p>\n \u00a0<\/p>\n Swipe or scroll to reveal the full table. Click headings to sort.<\/em><\/p>\n WordPress Tables Plugin<\/a><\/p>\n *Note: there was a 5:1 stock split for ACE<\/strong><\/p>\n \u00a0<\/p>\n There was only one listing over the past couple of weeks, Freedom Care Group (ASX:FCG)<\/strong><\/span>. The shares have traded sideways since listing on 30th November.<\/p>\n Freedom Care is a\u00a0National Disability Insurance Scheme (NDIS)<\/strong>\u00a0services provider head-quartered in Western Sydney that provides a full suite of allied health and care services to individuals accepted into the NDIS, predominantly in the greater Sydney area.<\/p>\n The business is now looking to expand both organically and by acquiring other NDIS providers.<\/p>\n The company says an ASX listing will allow it to pursue additional growth opportunities, including geographic expansion to areas outside of New South Wales and by expanding its current offerings.<\/p>\n Meanwhile, the best ASX IPO this year has been that of James Bay Minerals (ASX:JBY)<\/a><\/strong>.<\/p>\n The Canadian-based miner acquired a 100% interest in one of the largest lithium exploration portfolios in the James Bay region, covering an area of 34,572ha or 346km2.<\/p>\n James Bay has reported some positive news recently.<\/p>\n In early November, the company said it has strategically increased its La Grande Project area by 70% to 30,168ha (302km2) in James Bay, Canada.<\/p>\n The La Grande Project landholding has been strategically increased by 12,116ha (121km2), while the Aqua Property, which directly adjoins and sits along trend from FIN Resources\u2019 (ASX:FIN)<\/a> recent outcropping spodumene discovery, has been increased by 5,578ha (56km2).<\/p>\n The company\u2019s La Grande Project is a highly prospective lithium property located along trend from Winsome Resources\u2019 (ASX: WR1)<\/a> Cancet Lithium Project, and Patriot Battery Metals\u2019 (ASX:PMT)<\/a> world-class CV5 deposit.<\/p>\n This week, the company reported that a significant number of new LCT pegmatite targets have been generated from airborne LiDAR at the Aqua Property.<\/p>\n \u00a0<\/p>\n All dates are sourced from the ASX website. They could change without notice.<\/strong><\/p>\n \u00a0<\/p>\n Expected listing: December 11th<\/strong> LTR Pharma is a clinical stage, biotech company pioneering a novel intranasal technology \u2013 SPONTAN<\/strong> \u2013 designed to treat erectile dysfunction<\/strong> in 10 minutes or less.<\/p>\n SPONTAN is said to provide on-demand delivery and faster effect. A lower dose provides less systematic exposure and reduced side effect.<\/p>\n According to LTP, benefits of SPONTAN include enhanced trans mucosal absorption, increased bioavailability and lower drug dose.<\/p>\n Erectile Dysfunction (ED) is a condition in which you are unable to get or keep an erection firm enough for satisfactory sexual intercourse. ED can be a short-term or long-term problem.<\/p>\n LTP is targeting a US FDA New Drug Application (NDA) filing for SPONTAN, which is expected to be completed by the end of the first quarter of 2025 under the 505(b)(2) approval pathway regulatory strategy.<\/p>\n \u00a0<\/p>\n Expected listing: December 18th<\/strong> Enlitic is a healthcare IT company that harnesses AI to manage medical imaging data in radiology, such as MRI, CT, X-ray and ultrasound images.<\/p>\n The Enlitic platform<\/strong> standardises, protects, and\u00a0analyses data to create a database that improves clinical\u00a0workflows, increases efficiencies, and expands capacity.<\/p>\n The company says it owns the industry\u2019s first localised real-world medical imaging database that unlocks the value of historical diagnostic images, aligned with real-time diagnostics, and linkage to real-world data across any critical care solutions.<\/p>\n Health care providers using the Enlitic platform would have their productivity increased, and have their costs decreased, says the company.<\/p>\n \u00a0<\/p>\n Expected listing: December 18th<\/strong> Fuse has three ongoing minerals exploration projects \u2013\u00a0 Mt Sydney and Mt Sandman in WA, and Eastern Isaac in Queensland.<\/p>\n The flagship Mt Sydney Project<\/strong> covers a strategic landholding (100%-ownership) of 1119km2, and is located on the under-explored Pilbara Craton-Paterson Province margin in WA.<\/p>\n Fuse\u2019s work on the Mt Sydney Project to date shows VHMS gossans high-grade polymetallic vein outcrops mineralised breccia, and magmatic copper-nickel drill targets across this very large area of tenure.<\/p>\n The project has \u00a0limited past exploration, with only 1106m of drilling over 484km2.<\/p>\n The Mt Sandman Project is situated on the complex boundary of two major tectonic units of WA \u2013 the Proterozoic Gascoyne Province and the Palaeozoic Carnarvon Basin.<\/p>\n Rock chipping has confirmed base metal association with barite and carbonate rocks up to 6g\/t Ag >1% Pb & 0.3% Zn.<\/p>\n The Eastern Isaac Project in Qld meanwhile is a 25% ownership project, with option to earn up to 80%.<\/p>\n The Project comprises three copper\/gold project areas totalling 637km2: Gotthardt of 93km2, Valkyrie of 254km2, and Hamilton Park of 290km2.<\/p>\n \u00a0<\/p>\n \u00a0<\/p>\n <\/span><\/p>\n The post IPO Wrap: Biggest IPO in years comes to Nasdaq, and LTR Pharma to wow ASX with erectile dysfunction drug<\/a> appeared first on Stockhead<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"On to the ASX\u2026<\/h2>\n
Here\u2019s how the 2023 ASX IPOs are performing<\/h2>\n
Upcoming ASX IPO listings<\/h2>\n
LTR Pharma (ASX:LTP)<\/span><\/h2>\n
\nIPO: $7m at $0.20<\/strong><\/p>\nEnlitic (ASX:ENL)<\/strong><\/span><\/h2>\n
\nIPO: $35m at $0.83<\/strong><\/p>\nFuse Minerals (ASX:FSE)<\/strong><\/span><\/h2>\n
\nIPO: $10m at $0.20<\/strong><\/p>\n